Serum Serine Peptidase Inhibitor Kazal-Type 1, Trypsinogens 1 to 3, and Complex of Trypsin 2 and α1-Antitrypsin in the Diagnosis of Severe Acute Pancreatitis.


Journal

Pancreas
ISSN: 1536-4828
Titre abrégé: Pancreas
Pays: United States
ID NLM: 8608542

Informations de publication

Date de publication:
03 2019
Historique:
pubmed: 13 2 2019
medline: 3 9 2019
entrez: 13 2 2019
Statut: ppublish

Résumé

We explored prediction of severe acute pancreatitis (AP) and development of organ dysfunction (OD). Serum concentrations of serine peptidase inhibitor Kazal type 1 (SPINK1), trypsinogen 1, trypsinogen 2, and trypsinogen 3, complex between trypsin 2 and α1-antitrypsin, serum C-reactive protein, creatinine, and pancreatic amylase were measured in 239 AP patients with disease onset within 72 hours. SPINK1 distinguished most accurately patients who later developed severe AP. The area under the receiver operating characteristic curve for SPINK1 was 0.742, followed by trypsinogen 2 (0.726), complex between trypsin 2 and α1-antitrypsin (0.657), creatinine (0.656), trypsinogen 1 (0.652), trypsinogen 3 (0.557), and C-reactive protein (0.499). With a cutoff of 166 μg/L, SPINK1 had a specificity of 93%, a sensitivity of 48%, and diagnostic odds ratio of 11.52. In multivariate logistic regression analysis, only SPINK1 was an independent predictor of severe AP among patients presenting without OD on admission (P < 0.001). Plasma levels of the biomarkers and creatinine correlated with the severity of AP and development of OD. In patients presenting without OD at admission, SPINK1 was an independent marker for later development of severe AP.

Identifiants

pubmed: 30747826
doi: 10.1097/MPA.0000000000001260
doi:

Substances chimiques

Biomarkers 0
alpha 1-Antitrypsin 0
PRSS2 protein, human 103964-84-7
Trypsin Inhibitor, Kazal Pancreatic 50936-63-5
Trypsinogen 9002-08-8
C-Reactive Protein 9007-41-4
Creatinine AYI8EX34EU
PRSS1 protein, human EC 3.4.21.4
PRSS3 protein, human EC 3.4.21.4
Trypsin EC 3.4.21.4

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

374-380

Auteurs

Outi Itkonen (O)

Department of Clinical Chemistry, University of Helsinki, Helsinki, Finland.

Ulf-Håkan Stenman (UH)

Department of Clinical Chemistry, University of Helsinki, Helsinki, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH